Capmatinib new price released in 2024

Capmatinib is a targeted therapy drug that belongs to the category of small molecule kinase inhibitors. Its main application area is the treatment of METexon 14 skipping mutations in non-small cell lung cancer (NSCLC), which is a rare but biologically important type of mutation.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.

METexon14 skipping mutation is a specific mutation that affects the MET gene, causing abnormal activation of MET kinase activity, promoting the growth and spread of tumor cells. Capmatinib interferes with the signal transduction of tumor cells by inhibiting the abnormal activation of the MET pathway, thereby inhibiting the development of tumors.

Capmatinib was developed to precisely interfere with the activity ofMETkinase, making it a highly specific targeted drug. This specificity allows it to show excellent efficacy in patients with MET exon 14 skipping mutant NSCLC. Clinical trials have shown that capmatinib can significantly improve patients' objective response rate and prolong survival, bringing new treatment hope to patients with this specific subtype of lung cancer.

Capmatinib is usually used in the form of oral medication, and the specific dosage and course of treatment are determined by doctors based on the patient's specific conditions and pathological characteristics. Patients need to receive regular monitoring and evaluation by doctors during the use of capmatinib to ensure the efficacy and safety of the drug.